Lexeo Therapeutics rises as IPO research quiet period ends

Lexeo Therapeutics

28/11/2023 13:51

** Shares of Lexeo Therapeutics  LXEO.O  rise 7.3% to $11.8
premarket as IPO research quiet period ends
    ** Stifel initiates coverage with "Buy;" Leerink and RBC
start with "Outperform"
    ** Stifel, Leerink Partners and RBC were among 5 brokerages
that were the underwriters for the IPO
    ** Stifel says that LXEO's valuation is mostly driven by its
gene therapy LX2006 for a type of heart muscle disease that
causes suffering and death in 80% of patients
    **  Co's Alzheimer’s therapy LX1001 in March last year
showed reductions in proteins that cause cognitive decline in an
early-to-mid stage study
    ** Up to Monday's close, stock up 9.5% from close of trade
on its Nov. 3 Nasdaq debut

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))